Evidence map›Paper›PMID 36540387›Full record

ArticleOpen forum infectious diseases2022

Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.

Simiso Sokhela, Bronwyn Bosch, Andrew Hill, Bryony Simmons, Joana Woods, Hilary Johnstone, Shabir Madhi, Ambar Qavi, Leah Ellis, Godspower Akpomiemie and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Simiso SokhelaEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0002-2707-1533
Bronwyn BoschEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Andrew HillDepartment of Pharmacology and Therapeutics, Liverpool University, Liverpool, United Kingdom.
Bryony SimmonsLSE Health, London School of Economics and Political Science, London, United Kingdom.
Joana WoodsEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Hilary JohnstoneHJ-Clinical Trial Consultancy, George, South Africa.
Shabir MadhiSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Ambar QaviSchool of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-2496-1979
Leah EllisSchool of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom.
Godspower AkpomiemieEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Esther BhaskarEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Jacob LeviDepartment of Intensive Care Medicine, Royal Free Hospital NHS Trust, London, United Kingdom.ORCID https://orcid.org/0000-0003-0206-7121
Jonathan FalconerRespiratory Department, Royal Brompton Hospital NHS Trust, London, United Kingdom.
Manya MirchandaniSchool of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom.
Carmen Perez CasasUnitaid, Global Health Campus, Le Grand-Saconnex, Switzerland.
Karlien MollerEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Victoria PilkingtonOxford University Clinical Academic Graduate School, Oxford, United Kingdom.
Toby PepperrellCollege of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Willem Daniel Francois VenterEzintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In high-risk individuals in Johannesburg, during the Delta coronavirus disease 2019 wave, 22% (125/561) were positive, with 33% symptomatic (2 hospitalizations; 1 death). During Omicron, 56% (232/411) were infected, with 24% symptomatic (no hospitalizations or deaths). The remarkable speed of infection of Omicron over Delta poses challenges to conventional severe acute respiratory syndrome coronavirus 2 control measures.

Indexed as

COVID-19DeltaOmicronSARS-CoV-2South Africa

Identifiers

PMID36540387
PMCPMC9757672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.